UKTI Life Sciences Mission to Japan
13-17 February 2012

Please note the deadline for applications is Wednesday 30th November

Click here for applications for the Life Sciences Mission to Japan on 13-17 Feb 2012

Click here to view the full flyer

Cost: £1,110 – mission participation to seminars and networking receptions in Tokyo and Osaka

In addition, companies have access to “Nano Tech 2012” (www.nanotechexpo.jp/en/index.html), and to advice from UKTI colleagues from British Embassies in South Korea and Taiwan.

Why Japan?
Japan is the world’s 2nd largest pharmaceutical market in the world worth £65bn. At 11% of the global market, it is bigger than France and Germany combined
Japanese Biotech & Pharma companies have been proactively looking for R&D and in-licensing partners who can offer them promising drug candidates, novel DDS, formulations and also biomarkers
Opportunities also exist in services that enable pharmaceutical companies to reduce drug development times
Japan is the world’s 2nd largest healthcare market, with the imports of medical devices market alone worth around £8bn
Japanese Health & Medtech companies are urgently looking to acquire new research and product development pipelines from overseas
The Japanese government has reduced drug/device approval times. With the highest proportion of elderly people in the world, it is a long-term growth market

What is available from the Mission?
Opportunity to access key decision-makers and find future business partners within this lucrative market
UKTI will contact 1500 leading Japanese opinion formers in advance of your visit to showcase your company
Opportunity to present to and network with 100 decision makers from Japanese Biotech & Pharmaceuticals industry and Healthcare & Medtech industry

Previous Delegates:

• Biotech/Pharma – Takeda, Eisai, Astellas, Daiichi-Sankyo, Mitsubishi Tanabe, Otsuka, Shionogi, Kyowa Hakko Kirin
• Healthcare/Medical – Olympus, Terumo, Hitachi, Nihon Kohden, Sysmex, Panasonic Healthcare 

Previous Delegate Success:

• UK Heat Treatment technology company estimated receving £100K-250K over the next 2 years as a direct result of the mission
• An assistive product maker has also established a wide distribution network in Japan